Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
590M
-
Number of holders
-
1204
-
Total 13F shares, excl. options
-
494M
-
Shares change
-
-894K
-
Total reported value, excl. options
-
$40.9B
-
Value change
-
-$10.6M
-
Put/Call ratio
-
0.63
-
Number of buys
-
523
-
Number of sells
-
-560
-
Price
-
$82.63
Significant Holders of Edwards Lifesciences Corp - Common Stock (EW) as of Q3 2022
1,378 filings reported holding EW - Edwards Lifesciences Corp - Common Stock as of Q3 2022.
Edwards Lifesciences Corp - Common Stock (EW) has 1,204 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 494M shares
of 590M outstanding shares and own 83.76% of the company stock.
Largest 10 shareholders include BlackRock Inc. (52.4M shares), VANGUARD GROUP INC (50.9M shares), STATE STREET CORP (26.8M shares), Capital International Investors (22.7M shares), Bank of New York Mellon Corp (20.3M shares), ALLIANCEBERNSTEIN L.P. (17.2M shares), WELLINGTON MANAGEMENT GROUP LLP (14.6M shares), BROWN ADVISORY INC (14.2M shares), GEODE CAPITAL MANAGEMENT, LLC (11.9M shares), and SANDS CAPITAL MANAGEMENT, LLC (10.4M shares).
This table shows the top 1204 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.